At Merck, Merck Healthcare are proud to support the MS community, with over 25 years of research dedicated to advancing MS care and improving the lives of people living with MS. We are excited for you to join us at ECTRIMS 2025, where we will be sharing data from the latest clinical trials and real-world studies, and highlighting what these findings mean for patients.
Our medical symposium “Breaking the MS barrier: moving toward optimal disease control” will take place on Wednesday, 24 September at 13:15–14:15 CEST in the Auditorium. This symposium will be co-chaired by MS experts Gavin Giovannoni and Celia Oreja-Guevara, who will be joined by Christoph Kleinschnitz, Gabriel Pardo and Jai S. Perumal. Together, they will discuss the importance of treating MS early and holistically to preserve the brain and its function, and how real-world evidence can help guide MS management. Click here to add this session to your calendar.
This year, we will be providing several opportunities to discuss how MS treatment goals have evolved and exploring how we can continue to strive to improve disease management. This includes by targeting both peripherally-initiated and central compartmentalized inflammation, which contribute to neurodegeneration and can lead to cognitive decline early in the disease course.1-5 Targeting these processes early may reduce the risk of neuronal damage and improve long-term patient outcomes.5,6
We will also be highlighting how new insights from real-world data are helping to inform the management of MS in patient populations under-represented in clinical trials and guide long-term patient management. Post-approval data is advancing our understanding of DMTs’ long-term safety and efficacy. Immune reconstitution therapies have demonstrated sustained efficacy in phase IV and real-world studies, while the protective immune response is restored post-reconstitution.7-9
We look forward to connecting with you at ECTRIMS 2025 to foster a deeper understanding of the different treatment modalities in MS and how to manage patients. Visit us at the Merck exhibition booth to hear more.
Stay in the loop with all our medical activities at ECTRIMS 2025, here on the Merck at ECTRIMS microsite.
References
1. Pitteri M et al. Mult Scler 2017; 23 :848–54
2. Kuhlmann T et al. Lancet Neurol 2023; 22: 78–88
3. Filippi M et al. Nat Rev Dis Primers 2018; 4:43
4. Oh J et al. Mult Scler 2021; 27: 2199–208
5. Singer BA et al. J Neurol 2024; 271: 3116–30
6. He A et al. Lancet Neurol 2020; 19: 307–16
7. Sørenson PS, Sellebjerg F. Ther Adv Neurol Disord 2019; 12: 1756286419836913
8. Giovannoni G. Curr Opin Neurol 2018; 31: 233–43
9. Giovannoni G, Mathews J. Neurol Ther 2022; 11: 571–95